Emmaus Life Sciences Announces Submission of Endari® Marketing Authorization Application in KuwaitPRNewsWire • 07/15/21
Emmaus Life Sciences Announces Submission of Marketing Authorization Application to Swissmedic Ideogen, A.G. to Manage Early Access ProgramPRNewsWire • 06/15/21
Emmaus Life Sciences Announces Submission of Marketing Authorization Application for Endari® to the Saudi Food & Drug AuthorityPRNewsWire • 05/26/21
Emmaus Life Sciences Reports Annual Financial Results for 2020 and Provides Updated Business ReviewPRNewsWire • 05/04/21
UPDATE - Emmaus Life Sciences Announces Submission of Marketing Authorization Application to the Saudi Food and Drug AuthorityGlobeNewsWire • 08/18/20
Emmaus Life Sciences Announces Submission of Marketing Authorization Application to the Saudi Food and Drug AuthorityGlobeNewsWire • 08/18/20
Emmaus Life Sciences Reports Additional Positive Preliminary Results in Diverticulosis Pilot TrialGlobeNewsWire • 08/05/20
Emmaus Life Sciences Receives Scientific Advice From the EMA Regarding Xyndari™GlobeNewsWire • 07/29/20
Emmaus Life Sciences Accelerates Middle East and North Africa (MENA) Growth Strategy with Opening of its Dubai OfficeGlobeNewsWire • 07/23/20
Emmaus Life Sciences Announces Engagement of Partner International to Lead Out-Licensing of Endari® for DiverticulosisGlobeNewsWire • 07/16/20
Emmaus Life Sciences Receives Endari® Marketing Authorization from the Israeli Ministry of HealthGlobeNewsWire • 06/29/20
National Institutes of Health Announces Intention with Respect to Grant of Exclusive Patent License to Emmaus Life SciencesGlobeNewsWire • 06/25/20